Jazz Pharmaceuticals Plc (JAZZ) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Incyte Corp.

Jazz Pharmaceuticals Plc

Alnylam Pharmaceuticals, Inc.

Neurocrine Biosciences, Inc.

Viatris, Inc.

United Therapeutics Corp.

Repligen Corp.

Royalty Pharma Plc

Sarepta Therapeutics, Inc.

Walgreens Boots Alliance, Inc.

Roivant Sciences Ltd.

Why is Jazz Pharmaceuticals Plc ?

Healthy long term growth as Net Sales has grown by an annual rate of 12.54%

With a growth in Operating Profit of 33.49%, the company declared Outstanding results in Jun 26

The company has declared positive results for the last 4 consecutive quarters
OPERATING CASH FLOW(Y) Highest at USD 1,661.04 MM
ROCE(HY) Highest at 22.11%
INTEREST COVERAGE RATIO(Q) Highest at 808.17

With ROCE of 7.99%, it has a fair valuation with a 1.96 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 128.91%, its profits have risen by 9.7% ; the PEG ratio of the company is 1.9

Market Beating performance in long term as well as near term

Along with generating 128.91% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Jazz Pharmaceuticals Plc should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Jazz Pharmaceuticals Plc for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Jazz Pharmaceuticals Plc

128.91%

3.63

37.34%

S&P 500

22.36%

1.70

13.18%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

12.54%

EBIT Growth (5y)

-5.43%

EBIT to Interest (avg)

2.75

Debt to EBITDA (avg)

2.97

Net Debt to Equity (avg)

0.67

Sales to Capital Employed (avg)

0.42

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

9.96%

ROE (avg)

10.20%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.60

EV to EBIT

24.48

EV to EBITDA

11.12

EV to Capital Employed

1.96

EV to Sales

3.32

PEG Ratio

1.93

Dividend Yield

ROCE (Latest)

7.99%

ROE (Latest)

14.85%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

23What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 1,661.04 MM

ROCE(HY)

Highest at 22.11%

INTEREST COVERAGE RATIO(Q)

Highest at 808.17

RAW MATERIAL COST(Y)

Fallen by -4.03% (YoY

CASH AND EQV(HY)

Highest at USD 5,074.1 MM

DEBT-EQUITY RATIO (HY)

Lowest at 46.01 %

NET SALES(Q)

Highest at USD 1,208.3 MM

OPERATING PROFIT(Q)

Highest at USD 504.3 MM

OPERATING PROFIT MARGIN(Q)

Highest at 41.74 %

PRE-TAX PROFIT(Q)

At USD 289.1 MM has Grown at 83.65%

NET PROFIT(Q)

At USD 264.2 MM has Grown at 51.41%

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Here's what is working for Jazz Pharmaceuticals Plc

Operating Cash Flow

Highest at USD 1,661.04 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Interest Coverage Ratio

Highest at 808.17

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Net Sales

Highest at USD 1,208.3 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD 504.3 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at 41.74 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

At USD 289.1 MM has Grown at 83.65%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

At USD 264.2 MM has Grown at 51.41%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Cash and Eqv

Highest at USD 5,074.1 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio

Lowest at 46.01 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by -4.03% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales